Login to Your Account

Clinic Roundup

Wednesday, February 9, 2011
Medicago Inc., of Quebec City, said the FDA cleared the firm to start a Phase I trial of its H1N1 virus-like particle vaccine candidate. The study is expected to test single, nonadjuvanted doses of the vaccine in 100 healthy adults, ages 18 to 49. Primary safety and immunogenicity data are expected within three months of the start of the study and are expected to support the company's development of a seasonal influenza VLP vaccine in the U.S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription